How is enclomiphene different from clomiphene (Clomid)?

Clomiphene contains two isomers: enclomiphene (trans) and zuclomiphene (cis). Zuclomiphene is an estrogen agonist with a long half-life that accumulates over time, contributing to side effects like mood changes, visual disturbances, and elevated estradiol. Enclomiphene is the pure anti-estrogenic isomer — it raises testosterone with significantly fewer adverse effects and lower estradiol elevation.

Why isn't enclomiphene FDA-approved?

Repros Therapeutics submitted enclomiphene (as Androxal) for FDA approval, but received a Complete Response Letter in 2015. The FDA determined the Phase 3 study design was no longer adequate and requested additional trials. After Allergan acquired Repros in 2017, development was discontinued in 2021. The studies were never completed — it's a business decision, not a safety issue.

Can enclomiphene replace TRT?

For secondary hypogonadism (where the problem is in the brain's signaling, not the testes themselves), enclomiphene can meaningfully raise testosterone — a meta-analysis showed an average increase of ~274 ng/dL. It preserves fertility and sperm production, unlike TRT. However, for primary hypogonadism (testicular failure), enclomiphene won't work because the testes can't respond to the increased LH/FSH signal.

Enclomiphene

The active isomer of clomiphene, a selective estrogen receptor modulator (SERM) that raises testosterone while preserving fertility. Not FDA-approved as a standalone drug, but widely available through compounding pharmacies.

ModerateModerate Data

What is Enclomiphene?

Enclomiphene is the trans-isomer of clomiphene citrate — the "active" half of Clomid that stimulates testosterone production. Unlike exogenous testosterone (TRT), which shuts down the body's own production and can cause infertility, enclomiphene works by blocking estrogen receptors in the hypothalamus, tricking the brain into producing more LH and FSH, which in turn stimulate the testes to make more testosterone and sperm. It is technically not a peptide — it's a small-molecule SERM — but it is widely discussed in the peptide and hormone optimization community as a fertility-preserving alternative to TRT. Enclomiphene was developed as Androxal by Repros Therapeutics, but FDA approval was denied in 2015 and development was discontinued in 2021. It remains available through compounding pharmacies under Section 503A, since it's a component of the FDA-approved drug clomiphene.

Why People Talk About It

Testosterone restoration while preserving fertility

Moderate

Alternative to TRT without HPG axis suppression

Moderate

Lower estradiol side effects vs. clomiphene (Clomid)

Moderate

Post-cycle therapy (PCT) after anabolic steroid use

Preliminary

Secondary hypogonadism in obese men

Moderate

How It Works

Enclomiphene blocks estrogen receptors in the brain's hypothalamus. Normally, estrogen signals the brain to slow down testosterone production. By blocking that signal, enclomiphene tricks the brain into thinking estrogen is low, causing it to release more LH and FSH — the hormones that tell the testes to produce more testosterone and sperm.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Generally well-tolerated — significantly fewer side effects than clomipheneHeadacheHot flashes (less common than clomiphene)Nausea (mild)

Cautions

• Not FDA-approved as a standalone drug
• Available through compounding pharmacies — quality varies by source
• Monitoring testosterone, estradiol, LH, FSH, and hematocrit recommended
• Contraindicated in primary hypogonadism (testicular failure)
• Banned by WADA — prohibited in competitive sports

What We Don't Know

Long-term safety data beyond 3 years is limited. Whether enclomiphene provides the same cardiovascular, bone density, and metabolic benefits as testosterone replacement is unclear. The compounding pharmacy supply chain lacks the quality controls of FDA-approved manufacturing.

Published Research

6 studies

Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.

10 RCTs, 819 patients, +274 ng/dL testosterone

Systematic ReviewPMID: 41066380

Safety and efficacy of enclomiphene and clomiphene for hypogonadal men.

Retrospective StudyPMID: 39434750

Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study.

Retrospective StudyPMID: 37546076

Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis.

Systematic ReviewPMID: 36604313

Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism.

ReviewPMID: 31063005

Enclomiphene citrate for the treatment of secondary male hypogonadism.

ReviewPMID: 27337642

Mechanism of Action

Enclomiphene is a selective estrogen receptor modulator (SERM) that competitively antagonizes estrogen receptor alpha (ERα) in the hypothalamus. By blocking estrogen-mediated negative feedback on GnRH neurons, it increases pulsatile GnRH secretion, leading to elevated LH and FSH release from the anterior pituitary. LH stimulates Leydig cell testosterone synthesis; FSH supports Sertoli cell function and spermatogenesis. Unlike exogenous testosterone, this preserves the hypothalamic-pituitary-gonadal (HPG) axis and maintains intratesticular testosterone concentrations necessary for sperm production. A meta-analysis of 10 RCTs (819 patients) showed SERMs increased total testosterone by 273.76 ng/dL, LH by 4.66 IU/L, and FSH by 4.59 IU/L vs placebo. Compared to testosterone gel, SERMs produced comparable testosterone levels with significantly higher LH and FSH — indicating preserved endogenous production rather than suppression. Enclomiphene specifically showed lower estradiol elevation than racemic clomiphene (-5.92 vs +17.50 pg/mL) and 82% lower odds of adverse events.

Evidence Snapshot

Overall Confidence65%

Human Clinical Evidence

Moderate. A 2025 systematic review and meta-analysis of 10 RCTs (819 patients) confirmed SERMs increase testosterone by ~274 ng/dL with preserved FSH/LH (Archives of Endocrinology and Metabolism). A 2024 head-to-head study (66 patients) showed enclomiphene had comparable testosterone increases to clomiphene but significantly lower estradiol elevation and 82% fewer adverse events (Translational Andrology and Urology). Multiple Phase 2/3 trials demonstrated testosterone normalization while preserving sperm counts. FDA approval was denied due to study design concerns, not safety or efficacy failures.

Animal / Preclinical

Limited — enclomiphene's mechanism is well-established from decades of clomiphene research. The clinical evidence base is the primary support.

Mechanistic Rationale

Strong. Hypothalamic estrogen receptor antagonism → increased GnRH → LH/FSH → testosterone is a well-validated endocrine pathway. The advantage of enclomiphene over racemic clomiphene (removing the estrogenic zuclomiphene isomer) is mechanistically straightforward and clinically confirmed.

Forms & Administration

Enclomiphene is taken as a once-daily oral capsule, typically 12.5-25 mg. It is available through compounding pharmacies with a prescription. Baseline and follow-up bloodwork (total testosterone, free testosterone, estradiol, LH, FSH, CBC) is recommended. All medications should only be used under the guidance of a qualified healthcare provider.